Elizabeth Halloran

(Reading, Writing, Speaking)

National Institutes of Health (NIH): Methods for Evaluating Vaccine Efficiency, 1999 to 2005.
National Institutes of Health (NIH): Methods for Evaluating Vaccine Efficiency, 1995 to 1999.
National Institutes of Health (NIH): Methods for Evaluating Vaccine Efficiency, 1992 to 1995.

• Longini IM Jr, Nizam A, Xu S, Ungchusak K, Hanshaoworakul W, Cummings DA, Halloran ME (Aug 2005) Containing pandemic influenza at the source, Science, 309 (5737), 1083-7
• Patel R, Longini IM Jr, Halloran ME (May 2005) Finding optimal vaccination strategies for pandemic influenza using genetic algorithms, Journal of Theoretical Biology, 234 (2), 201-12
• Longini IM Jr, Halloran ME (Feb 2005) Strategy for distribution of influenza vaccine to high-risk groups and children, American Journal of Epidemiology, 161 (4), 303-6
• Weycker D, Edelsberg J, Halloran ME, Longini IM Jr, Nizam A, Ciuryla V, Oster G (Jan 2005) Population-wide benefits of routine vaccination of children against influenza, Vaccine, 23 (10), 1284-93
• Chu H, Halloran ME (Sep 2004) Estimating vaccine efficacy using auxiliary outcome data and a small validation sample, Statistics in Medicine, 23 (17), 2697-711
• Glezen WP, Piedra PA, Longini IM, Halloran ME, Safety of cold-adapted live influenza vaccine, The Pediatric Infectious Disease Journal, 23(6), 593-4; author reply, Jun 2004
• Longini IM Jr, Halloran ME, Nizam A, Yang Y (Apr 2004) Containing pandemic influenza with antiviral agents, American Journal of Epidemiology, 159 (7), 623-33
• Cuenco KT, Halloran ME, Louis-Charles J, Lammie PJ (Feb 2004) A family study of lymphedema of the leg in a lymphatic filariasis-endemic area, The American Journal of Tropical Medicine and Hygiene, 70 (2), 180-4
• Cuenco KT, Halloran ME, Lammie PJ (Feb 2004) Assessment of families for excess risk of lymphedema of the leg in a lymphatic filariasis-endemic area, The American Journal of Tropical Medicine and Hygiene, 70 (2), 185-90
• Gaglani MJ, Piedra PA, Herschler GB, Griffith ME, Kozinetz CA, Riggs MW, Fewlass C, Halloran ME, Longini IM Jr, Glezen WP (Jan 2004) Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children, Archives of Pediatrics & Adolescent Medicine, 158 (1), 65-73
• Chu H, Preziosi MP, Halloran ME (Jan 2004) Estimating heterogeneous transmission with multiple infectives using MCMC methods, Statistics in Medicine, 23 (1), 35-49
• Chu H, Halloran ME (2004) Bayesian estimation of vaccine efficacy, Clin Trials, 1 (3), 306-14
• Preziosi MP, Halloran ME (Sep 2003) Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity, Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 37 (6), 772-9
• Halloran ME, Longini IM Jr, Gaglani MJ, Piedra PA, Chu H, Herschler GB, Glezen WP (Aug 2003) Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures, American Journal of Epidemiology, 158 (4), 305-11
• Preziosi MP, Halloran ME (May 2003) Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness, Vaccine, 21 (17-18), 1853-61
• Halloran ME, Longini IM Jr, Nizam A, Yang Y (Nov 2002) Containing bioterrorist smallpox, Science, 298 (5597), 1428-32
• Halloran ME, Longini IM, Cowart DM, Nizam A (Sep 2002) Community interventions and the epidemic prevention potential, Vaccine, 20 (27-28), 3254-62
• Longini IM Jr, Halloran ME, Nizam A (Feb 2002) Model-based estimation of vaccine effects from community vaccine trials, Statistics in Medicine, 21 (4), 481-95
• Hudgens MG, Longini IM Jr, Vanichseni S, Hu DJ, Kitayaporn D, Mock PA, Halloran ME, Satten GA, Choopanya K, Mastro TD (Jan 2002) Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand, American Journal of Epidemiology, 155 (2), 159-68
• Halloran ME, Longini IM Jr (Sep 2001) Using validation sets for outcomes and exposure to infection in vaccine field studies, American Journal of Epidemiology, 154 (5), 391-8
• Longini IM, Halloran ME, Nizam A, Wolff M, Mendelman PM, Fast PE, Belshe RB (Mar 2000) Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control, Vaccine, 18 (18), 1902-9
• Datta S, Halloran ME, Longini IM Jr (Sep 1999) Efficiency of estimating vaccine efficacy for susceptibility and infectiousness: randomization by individual versus household, Biometrics, 55 (3), 792-8
• Golm GT, Halloran ME, Longini IM Jr (Mar 1999) Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials, Biometrics, 55 (1), 94-101
• Longini IM Jr, Hudgens MG, Halloran ME, Sagatelian K (Jan 1999) A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines, Statistics in Medicine, 18 (1), 53-68
• Halloran ME, Longini IM Jr, Struchiner CJ (1999) Design and interpretation of vaccine field studies, Epidemiologic Reviews, 21 (1), 73-88
• Golm GT, Halloran ME, Longini IM Jr (Oct 1998) Semi-parametric models for mismeasured exposure information in vaccine trials, Statistics in Medicine, 17 (20), 2335-52
• Durham LK, Longini IM Jr, Halloran ME, Clemens JD, Nizam A, Rao M (May 1998) Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines, American Journal of Epidemiology, 147 (10), 948-59
• Longini IM Jr, Sagatelian K, Rida WN, Halloran ME (May 1998) Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations, Statistics in Medicine, 17 (10), 1121-36
• Halloran ME, Anderson RM, Azevedo-Neto RS, Bellini WJ, Branch O, Burke MA, Compans R, Day K, Gooding L, Gupta S, Katz J, Kew O, Keyserling H, Krause R, Lal AA, Massad E, McLean AR, Rosa P, Rota P, Wiener P, Wynn SG, Zanetta DM (Feb 1998) Population biology, evolution, and immunology of vaccination and vaccination programs, The American Journal of the Medical Sciences, 315 (2), 76-86
• Stephens DS, Levin B, Halloran ME (Feb 1998) Symposium on population biology, evolution, and control of infectious diseases. Introduction, The American Journal of the Medical Sciences, 315 (2), 63
• Sun F, Ashley-Koch AE, Durham LK, Feingold E, Halloran ME, Manatunga AK, Sherman SL (1998) Testing for contributions of mitochondrial DNA mutations to complex diseases, Genetic Epidemiology, 15 (5), 451-69
• Datta S, Halloran ME, Longini IM Jr (Jan 1998) Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy, Statistics in Medicine, 17 (2), 185-200
• Halloran ME, Struchiner CJ, Longini IM Jr (Nov 1997) Study designs for evaluating different efficacy and effectiveness aspects of vaccines, American Journal of Epidemiology, 146 (10), 789-803
• Bertolli J, Pangi C, Frerichs R, Halloran ME (Aug 1997) A case-control study of the effectiveness of BCG vaccine for preventing leprosy in Yangon, Myanmar, International Journal of Epidemiology, 26 (4), 888-96
• Longini IM Jr, Datta S, Halloran ME (Dec 1996) Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines, Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association, 13 (5), 440-7
• Mosure DJ, Berman S, Kleinbaum D, Halloran ME (Nov 1996) Predictors of Chlamydia trachomatis infection among female adolescents: a longitudinal analysis, American Journal of Epidemiology, 144 (10), 997-1003
• Halloran ME (Sep 1996) Epidemiologic effects of varicella vaccination, Infectious Disease Clinics of North America, 10 (3), 631-55
• Halloran ME, Longini IM Jr, Struchiner CJ (Jul 1996) Estimability and interpretation of vaccine efficacy using frailty mixing models, American Journal of Epidemiology, 144 (1), 83-97
• Antia R, Halloran ME (Jul 1996) Recent developments in theories of pathogenesis of AIDS, Trends in Microbiology, 4 (7), 282-5
• Haber M, Watelet L, Halloran ME (Dec 1995) On individual and population effectiveness of vaccination, International Journal of Epidemiology, 24 (6), 1249-60
• Noronha CP, Struchiner CJ, Halloran ME (Oct 1995) Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study, International Journal of Epidemiology, 24 (5), 1050-7
• Haber M, Orenstein WA, Halloran ME, Longini IM Jr (May 1995) The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreak, American Journal of Epidemiology, 141 (10), 980-90
• Longini IM Jr, Halloran ME, AIDS: modeling epidemic control, Science, 267(5202), 1250-1; author reply, Mar 1995
• Halloran ME, Struchiner CJ (Mar 1995) Causal inference in infectious diseases, Epidemiology (cambridge, Mass.), 6 (2), 142-51
• Devine OJ, Louis TA, Halloran ME (Nov 1994) Empirical Bayes methods for stabilizing incidence rates before mapping, Epidemiology, 5 (6), 622-30
• Halloran ME, Cochi SL, Lieu TA, Wharton M, Fehrs L (Jul 1994) Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States, American Journal of Epidemiology, 140 (2), 81-104
• Halloran ME, Watelet L, Struchiner CJ (Jun 1994) Epidemiologic effects of vaccines with complex direct effects in an age-structured population, Mathematical Biosciences, 121 (2), 193-225
• Lieu TA, Cochi SL, Black SB, Halloran ME, Shinefield HR, Holmes SJ, Wharton M, Washington AE (Feb 1994) Cost-effectiveness of a routine varicella vaccination program for US children, Jama : the Journal of the American Medical Association, 271 (5), 375-81
• Halloran ME, Longini IM Jr, Haber MJ, Struchiner CJ, Brunet RC (Feb 1994) Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field, Statistics in Medicine, 13 (4), 357-77
• Halloran ME (Dec 1993) Salmonella enteritidis infections in France and the United States: causes vs causal models, American Journal of Public Health, 83 (12), 1667-9
• Brunet RC, Struchiner CJ, Halloran ME (Jul 1993) On the distribution of vaccine protection under heterogeneous response, Mathematical Biosciences, 116 (1), 111-25
• Longini IM Jr, Halloran ME, Haber M, Chen RT (Feb 1993) Measuring vaccine efficacy from epidemics of acute infectious agents, Statistics in Medicine, 12 (3-4), 249-63
• Longini IM Jr, Halloran ME, Haber M (Sep-Oct 1993) Estimation of vaccine efficacy from epidemics of acute infectious agents under vaccine-related heterogeneity, Mathematical Biosciences, 117 (1-2), 271-81
• Halloran ME, Haber M, Longini IM Jr (Aug 1992) Interpretation and estimation of vaccine efficacy under heterogeneity, American Journal of Epidemiology, 136 (3), 328-43
• Struchiner CJ, Halloran ME (Jan-Mar 1992) Modeling AIDS vaccines: the cellular level, Memorias Do Instituto Oswaldo Cruz, 87 (1), 103-13
• Haber M, Longini IM Jr, Halloran ME (Oct 1991) Estimation of vaccine efficacy in outbreaks of acute infectious diseases, Statistics in Medicine, 10 (10), 1573-84
• Halloran ME, Struchiner CJ (Sep 1991) Study designs for dependent happenings, Epidemiology, 2 (5), 331-8
• Haber M, Longini IM Jr, Halloran ME (Mar 1991) Measures of the effects of vaccination in a randomly mixing population, International Journal of Epidemiology, 20 (1), 300-10
• Halloran ME, Haber M, Longini IM Jr, Struchiner CJ (Feb 1991) Direct and indirect effects in vaccine efficacy and effectiveness, American Journal of Epidemiology, 133 (4), 323-31
• Longini IM Jr, Haber MJ, Halloran ME (Jul 1990) [Direct and indirect effects of vaccines: an annotation on the estimation of the vaccine efficacy from outbreaks caused by acute infection agents such as measles], Boletin Medico Del Hospital Infantil De Mexico, 47 (7), 516-9
• Struchiner CJ, Halloran ME, Robins JM, Spielman A (Mar 1990) The behaviour of common measures of association used to assess a vaccination programme under complex disease transmission patterns--a computer simulation study of malaria vaccines, International Journal of Epidemiology, 19 (1), 187-96
• Struchiner CJ, Halloran ME, Spielman A (May 1989) Modeling malaria vaccines. I: New uses for old ideas, Mathematical Biosciences, 94 (1), 87-113
• Halloran ME, Struchiner CJ, Spielman A (May 1989) Modeling malaria vaccines. II: Population effects of stage-specific malaria vaccines dependent on natural boosting, Mathematical Biosciences, 94 (1), 115-49